VALERIA BUCCHERI

(Fonte: Lattes)
Índice h a partir de 2011
8
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 46
  • article 0 Citação(ões) na Scopus
    Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry
    (2023) GOVEIA, Lilian; CASTRO, Nelson; SOUZA, Carmino de; VILLARIM, Carolina Colaco; TRAINA, Fabiola; CHIATTONE, Carlos Sergio; PRAXEDES, Monica; SOLZA, Cristiana; PEROBELLI, Leila; BAIOCCHI, Otavio; GAIOLLA, Rafael; BOQUIMPANI, Carla; BUCCHERI, Valeria; SOLA, Caroline Bonamin; SILVA, Roberta de Oliveira Paula e; RIBAS, Ana Carolina; STEFFENELLO, Giovanna; PAGNANO, Katia; SOARES, Andrea; MEDINA, Samuel Souza; SILVEIRA, Talita; CECYN, Karin Zattar; PALMA, Leonardo Carvalho; MARQUES, Mariana de Oliveira; SPECTOR, Nelson; BIASOLI, Irene
    The treatment of older patients with Hodgkin lymphoma (HL) remains a challenge. We sought to identify the treatment patterns and outcomes in older HL patients included in the Brazilian HL registry (NCT02589548). A total of 136 patients with HIV-negative classic HL, aged & GE; 60 years, diagnosed between 2009 and 2018, were analyzed. The median age was 66 years old (60-90), 72% had advanced disease, 62% had a high IPS, and 49% had a nodular sclerosis subtype. Median follow-up was 64 months for alive patients. ABVD was the front-line treatment in 96% of patients. Twenty-one patients (15%) died during front-line treatment. The 5-year PFS and 5-year OS rates were 55% and 59%, respectively. The 5-year OS rates in localized and advanced disease were 81% and 51% (p=0.013). Lung toxicity developed in 11% of the patients treated with ABVD. Bleomycin was administered for > 2 cycles in 65% of patients. Compared with 2009-2014, there was a decrease in the use of bleomycin for > 2 cycles in 2015-2018 (88% x 45%, p<0.0001). The impact of socioeconomic status (SES) on outcomes was studied in patients treated with ABVD. After adjusting for potential confounders, lower SES remained independently associated with poorer survival (HR 2.22 [1.14-4.31] for OS and HR 2.84 [1.48-5.45] for PFS). Treatment outcomes were inferior to those observed in developed countries. These inferior outcomes were due to an excess of deaths during front-line treatment and the excessive use of bleomycin. SES was an independent factor for shorter survival.
  • bookPart
    Leucemia linfocítica crônica
    (2016) BUCCHERI, Valeria
  • article 3 Citação(ões) na Scopus
    Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the F-18-fluorodeoxyglucose-positron emission tomography era
    (2015) GONCALVES, Marianne de Castro; PAULA, Henrique Moura de; LINARDI, Camila da Cruz Gouveia; CERCI, Juliano J.; ALDRED, Vera Lucia; SIQUEIRA, Sheila Aparecida Coelho; BUCCHERI, Valeria; ZERBINI, Maria Claudia Nogueira
    Bone marrow biopsy is recommended for staging of classical Hodgkin lymphoma. The aim of this study was to compare bone marrow evaluation by histology with that obtained by F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET). One hundred and three cases of Classical Hodgkin Lymphoma were reviewed. All patients were submitted to FDG-PET evaluation. Bone marrow biopsy results were compared with clinical data and FDG-PET results. Ninety-one cases had available bone marrow biopsies. Overall, there were 16 positive and one suspect case. In five cases, the FDG-PET scan was positive and biopsy was negative: 1/5 was found to correspond to a bone fracture, 3/5 showed marked reactive bone marrow changes and in 1/5 no explanation for the discrepancy was found. FDG-PET showed high sensitivity, supporting the idea that when it is negative, biopsy could be avoided. Care should be taken in patients with a positive FDG-PET, where confirmation by bone marrow biopsy should be recommended.
  • article 27 Citação(ões) na Scopus
    Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia
    (2016) RODRIGUES, Celso Arrais; GONÇALVES, Matheus Vescovi; IKOMA, Maura Rosane Valério; LORAND-METZE, Irene; PEREIRA, André Domingues; FARIAS, Danielle Leão Cordeiro de; CHAUFFAILLE, Maria de Lourdes Lopes Ferrari; SCHAFFEL, Rony; RIBEIRO, Eduardo Flávio Oliveira; ROCHA, Talita Silveira da; BUCCHERI, Valeria; VASCONCELOS, Yuri; FIGUEIREDO, Vera Lúcia de Piratininga; CHIATTONE, Carlos Sérgio; YAMAMOTO, Mihoko
    ABSTRACT Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for the diagnosis and treatment of chronic lymphocytic leukemia. The following recommendations are based on an extensive literature review with the aim of contributing to more uniform patient care in Brazil and possibly in other countries with a similar social-economic profile.
  • article 6 Citação(ões) na Scopus
    Current role of interferon in hairy cell leukemia therapy: a timely decision
    (2019) SILVA JUNIOR, Wellington Fernandes da; TEIXEIRA, Larissa Lane Cardoso; ROCHA, Vanderson; BUCCHERI, Valeria
  • conferenceObject
    Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab
    (2012) ASSOULINE, Sarit; BUCCHERI, Valeria; DELMER, Alain; DOELKEN, Gottfried; GAIDANO, Gianluca; MCINTYRE, Christine; BREWSTER, Mike; HOURCADE-POTELLERET, Florence; SAYYED, Pakeeza; BADOUX, Xavier
    Rituximab in combination with fludarabine and cyclophosphamide (FC) is recommended as the standard treatment for patients (pts) with chronic lymphocytic leukemia (CLL) where the goal of therapy is to achieve complete remission (ESMO Clinical Practice Guidelines, Ann Oncol 2011). Rituximab is currently administered intravenously (IV) where infusions may take several hours. A subcutaneous (SC) formulation of rituximab has been developed which could significantly shorten administration times, increasing patient convenience and potentially improving tolerability. Here we report part 1 data of a two part, randomized, open-label Phase Ib study of rituximab SC + FC vs rituximab IV + FC in previously untreated pts with CLL (SAWYER [BO25341]). The part 1 objectives were to ensure that the SC dose predicted from the BP22333 study (Salar et al. EHA 2012; ASH 2010) would result in comparable trough serum rituximab concentration (Ctrough) to IV in the CLL setting, and to assess safety and tolerability. Pts (≥18 years old) were enrolled in the study at any point during their initial standard treatment with rituximab IV + FC x 6, prior to commencement of Cycle 5. In Cycle 5, pts received rituximab at 500mg/m2 IV + FC and in Cycle 6 rituximab IV was replaced with rituximab SC at 1400 mg, 1600 mg or 1870 mg. Rituximab PK was evaluated on an ongoing basis throughout Cycles 5 and 6 and integrated into a population PK model using nonlinear mixed effects modeling. Model-based simulations were performed to predict serum Ctrough and AUC for various rituximab SC fixed doses (1400–1650 mg). A total of 64 pts were enrolled in part 1 of the study, 55 of these received rituximab SC + FC at doses of either 1400 mg (n=16), 1600 mg (n=17) or 1870 mg (n=22). Eight pts discontinued treatment prior to Cycle 6 and one pt enrolled to receive 1870 mg rituximab SC at Cycle 6 received a lower dose in error. The median age of pts was 60 years and pts were classified as Binet stage A (27%), B (55%), or C (19%). At Cycle 6, predicted mean Ctrough values for a fixed dose of 1600 mg rituximab SC were 75.2 μg/ml (90% CI: 60.1–90.1 μg/ml) compared with 62.5 μg/ml (90% CI: 49.4–73.6 μg/ml) for a 500 mg/m2 dose of rituximab IV. Furthermore, AUC values for 1600 mg rituximab SC were 3760 μg/ml (90% CI: 3250–4240 μg/ml) compared with 3470 μg/ml (90% CI: 3100–3820 μg/ml) for 500 mg/m2 rituximab IV, suggesting that a rituximab SC dose of 1600 mg would result in a Ctrough and AUC non-inferior to that of the approved IV regimen, independent of pt body surface area. The majority of adverse events (AEs) reported over the course of Cycles 5 plus 6 were grade 1 or 2 in intensity with 10/16 (63%) pts in the 1400 mg group, 11/17 (65%) pts in the 1600 mg group and 20/22 (91%) pts in the 1870 mg group reporting at least one AE. More pts experienced at least one grade ≥3 AE during Cycle 5 (19 pts following rituximab IV) than Cycle 6 (11 pts following rituximab SC) with the most common grade ≥3 AE reported being neutropenia. Two serious AEs occurred in Cycle 5 and two in Cycle 6. There were no deaths and no withdrawals from treatment due to AEs during Cycles 5 and 6. AEs that occurred during or within 24 h of the administration and were assessed by the investigator as related to rituximab IV/SC were defined as administration-related reactions (ARRs). Two pts reported ARRs at Cycle 5 compared with 12 pts at Cycle 6, with the majority of the Cycle 6 ARRs being related to local injection site reactions. After Cycle, 6 pts and nurses were asked if they preferred SC or IV administration. Of the 56 questionnaires completed, over 90% of pts and their treating nurses preferred the SC route of administration. In conclusion, results of the population PK analysis propose the selection of a 1600 mg rituximab SC fixed dose for pts with CLL to be administered in part 2 of the study. Safety profiles for rituximab SC were comparable with rituximab IV. A greater number of ARRs were observed after treatment with rituximab SC, these were mainly transient injection site pain and erythema. Questionnaire results after one cycle of rituximab SC indicated clearly that the preferred route of administration, for both nurses and pts was SC. In this study FC could be administered IV or orally; the opportunity to administer FC orally permits the possibility of a chemoimmunotherapy free from IV infusions. The study is ongoing to establish non-inferiority in observed Ctrough levels between the confirmed rituximab SC dose and the reference rituximab IV dose. Disclosures: Assouline: Roche: Honoraria. Off Label Use: Subcutaneous rituximab in combination with fludarabine and cyclophosphamide for patients with CLL. Delmer: French Society of Hematology: Consultancy, Honoraria, Research Funding, participation in French advisory board Other. Gaidano: Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Participated in Advisory Boards Other; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Participated in Advisory Boards, Participated in Advisory Boards Other; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Participated in Advisory Boards, Participated in Advisory Boards Other; Onyx: Consultancy, Membership on an entity's Board of Directors or advisory committees, Participated in Advisory Boards, Participated in Advisory Boards Other. McIntyre: Roche: Employment. Brewster: Roche: Employment, Equity Ownership. Hourcade-Potelleret: Roche: Employment. Sayyed: Roche: Employment.
  • bookPart
    Neutropenia
    (2013) VELOSO, Elvira D. R. Pereira; BUCCHERI, Valeria; LIMA, Walter de Macedo
  • conferenceObject
    Cytogenetic abnormalities in primary MDS: Incidence and classification according to cytogenetic risk groups defined by the IPSS and IPSS-R
    (2013) SILVA, M.; AZEVEDO NETO, R.; LEAL, A.; FERREIRA, P.; KUMEDA, C.; TANIZAWA, R.; MASCARENHAS, A.; LIMA, W.; BUCCHERI, V.; VELLOSO, E.
  • conferenceObject
    Ezrin Is a Potential Druggable Target in Chronic Lymphocytic Leukemia
    (2022) SILVA, Jean Carlos Lipreri Da; SALDANHA-ARAUJO, Felipe; MELO, Raphael Costa Bandeira de; VICARI, Hugo Passos; CARVALHO, Amandda Evelin Silva De; REGO, Eduardo M.; BUCCHERI, Valeria; MACHADO-NETO, Joao Agostinho
  • conferenceObject
    Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL
    (2022) LACERDA, Marcelo Pitombeira de; MARQUES, Fernanda de Morais; PFISTER, Verena; PARRA, Flavia de Carvalho; MOLLA, Vinicius Campos de; BUCCHERI, Valeria; GAIOLLA, Rafael Dezen; FOGLIATTO, Laura Maria; SANTUCCI, Rodrigo; BELLESSO, Marcelo; FORTIER, Sergio Costa; SILVEIRA, Talita M. B.; RIBEIRO, Glaciano; HAMERSCHLAK, Nelson; YAMAMOTO, Mihoko; GONCALVES, Matheus Vescovi; CHIATTONE, Carlos S.; ARRAIS-RODRIGUES, Celso